Question and Answer

Azrieli Group Reports Q4/2023 and Y2023 Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Azrieli Group, Property, Azrieli, Iron, Sale, Question and Answer, CBD, Bank Leumi, NOI, Bank statement, Investment, Lehavim, FFO

NIS 1 billion

Key Points: 
  • NIS 1 billion
    Danna Azrieli, Chairwoman of Azrieli Group: “2023 was a challenging year for Israeli society, even before the outbreak of the Iron Swords War.
  • Eyal Henkin, CEO of Azrieli Group: “We are ending a year full of activity and continued growth, with the relief given to the tenants of our malls due to the Iron Swords War having had a relatively moderate impact on the Q4 results.
  • NOI in Y2023 was up around 8% and totaled some NIS 2,113 million, compared with some NIS 1,953 million year-over-year.
  • The accounting effects of the transaction were recorded in Q4, and the operating results of Compass are not included starting from Q3/2023 results.

MineHub's Annual CEO Address to Shareholders; Announces Investor Webinar

Retrieved on: 
Thursday, January 4, 2024
Copper, Documentation, Ecosystem, Question and Answer, API, Sumitomo Corporation, Acquisition, Mining, Software as a service, ESG, Laboratory, Miner, PST, Growth, Transport, Codelco, Steel, CO2, Consolidation

MineHub will be hosting an investor webinar on Thursday, January 11, 2024, at 1:00 pm ET (10:00 am PST).

Key Points: 
  • MineHub will be hosting an investor webinar on Thursday, January 11, 2024, at 1:00 pm ET (10:00 am PST).
  • Our accelerated growth trajectory is a testament to the value our platform brings to partners and customers alike.
  • Increasing the Company's Annual Recurring Revenue ("ARR")(1) by executing new customer contracts and expanding volumes of commodities managed for existing customers.
  • MineHub will also be hosting an investor webinar to provide a corporate update and discuss its Q3-2024 Quarterly Results.

Castle Biosciences Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 2, 2023
General Health, Medical Devices, Other Health, Health, Medical Supplies, Adjustment, Laboratory, EAC, Metastasis, Innovation, The American Journal of Gastroenterology, Physician, Esophageal cancer, New York State Department of Health, EBITDA, Net, News, Cancer, GAAP, BE, Acquisition, Memorial Sloan Kettering Cancer Center, Sentinel lymph node, Workplace, Purpose, Risk, Compensation, Webcast, LGD, Question and Answer, Depreciation, HGD, Depression, American Journal, Table, Investment, Patient, Compensation and benefits, Pharmaceutical industry, Lithium, Video game, Film industry, Cryptocurrency, Clothing, Birth control, Medical imaging, Real estate

Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:

Key Points: 
  • Delivered 18,409 total test reports in the third quarter of 2023, an increase of 52% compared to 12,114 in the same period of 2022:
    DecisionDx®-Melanoma test reports delivered in the quarter were 8,559, compared to 7,354 in the third quarter of 2022, an increase of 16%.
  • DecisionDx®-SCC test reports delivered in the quarter were 2,820, compared to 1,636 in the third quarter of 2022, an increase of 72%.
  • MyPath® Melanoma test reports delivered in the quarter were 1,011, compared to 834 MyPath Melanoma and DiffDx®-Melanoma aggregate test reports in the third quarter of 2022, an increase of 21%.
  • Castle Biosciences will hold a conference call on Thursday, Nov. 2, 2023, at 4:30 p.m. Eastern time to discuss its third quarter 2023 results and provide a corporate update.

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

Retrieved on: 
Tuesday, February 7, 2023
Oncology, Health, Genetics, Research, Science, Biotechnology, Question and Answer, Webcast, Broadcasting

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.
  • Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
  • A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/697513364 or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx .
  • Please access the webcast at least 10 minutes before the conference call start time.

Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

Retrieved on: 
Friday, November 25, 2022
Carnegie Investment Bank, Radioimmunotherapy, Exercise, OSE, Government Pension Fund of Norway, CFO, Carnegie, Therapy, Interim, KPMG, Nordea, Proxy, Lymphocytosis, Question and Answer, CD37, APIM, Acquisition, Degenerative disease, Person, University, Judgement, CET, Question, Post office box, Webcast, Patient, Antibody, Risk management, Financial adviser, Audit

OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

Key Points: 
  • OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").
  • Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics.
  • After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before.
  • This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.

Nordic Nanovector Launches Dedicated Area on its Website in Norwegian for Information on the Proposed Merger with APIM Therapeutics

Retrieved on: 
Friday, November 25, 2022
Carnegie Investment Bank, Radioimmunotherapy, Exercise, OSE, Government Pension Fund of Norway, CFO, Carnegie, Therapy, Interim, KPMG, Nordea, Proxy, Lymphocytosis, Question and Answer, CD37, APIM, Acquisition, Degenerative disease, Person, University, Judgement, CET, Question, Post office box, Webcast, Patient, Antibody, Risk management, Financial adviser, Audit

OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").

Key Points: 
  • OSLO, Norway, Nov. 25, 2022 /PRNewswire/ --Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") has today launched a new dedicated area on its website ( www.nordicnanovector.com ) with information in Norwegian for shareholders relating to its proposed merger with APIM Therapeutics ("APIM").
  • Malene Brondberg, Interim CEO and CFO of Nordic Nanovector, says: "We are happy that so many shareholders attended the webcast we hosted yesterday, where we provided more background on the proposed merger with APIM Therapeutics.
  • After a week of highly productive meetings between the Nordic Nanovector and APIM teams, our confidence in a merged company is even stronger than before.
  • This review included carefully evaluating a potential stand-alone strategy for Nordic Nanovector, which was deemed not to be a viable option by the Board.

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

Retrieved on: 
Wednesday, October 19, 2022
Medical Devices, Other Health, Health, Pharmaceutical, Medical Supplies, LinkedIn, Question and Answer, Webcast, Investor relations, Patient, List of life sciences, Twitter, Instagram, Nasdaq, Company, Health, Atopic dermatitis, Skin, Uveal melanoma, View, Medical device, Facebook

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Key Points: 
  • Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
  • A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/748805907 or via the webcast link on the Investor Relations page of the Companys website , https://ir.castlebiosciences.com/overview/default.aspx .
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005130/en/

 Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Mental Health, Health, Other Health, Other Science, Science, Biotechnology, Securities Exchange Act of 1934, Health, Skin, Twitter, Securities Act of 1933, LinkedIn, Company, Atopic dermatitis, Skin cancer, Patient, Investment, Gastroenterology, Event, Instagram, Question and Answer, Uveal melanoma, Nasdaq, DecisionDx-UM, Research, SEC, Webcast, Medicine, Online shopping, Facebook

During its Investor Day today, senior leaders of Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present the Companys foundational guideposts exceptional employees, continuous evolution and improvement, and customer and solution centric as well as three-year financial targets.

Key Points: 
  • During its Investor Day today, senior leaders of Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present the Companys foundational guideposts exceptional employees, continuous evolution and improvement, and customer and solution centric as well as three-year financial targets.
  • Prepared remarks for Castles Investor Day will begin today at 4:00 p.m. Eastern time, followed by a Question & Answer session.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

The Christopher & Dana Reeve Foundation Quality of Life Program Announces Two New Grant Programs: Racial Equity & Rural Unserved and Underserved Populations

Retrieved on: 
Wednesday, August 31, 2022
Christopher and Dana Reeve Foundation, Administration for Community Living, Quality, Telephone, BBB, Caregiver, Research, India–Singapore Comprehensive Economic Cooperation Agreement, United States Department of Health and Human Services, Quality of life, Program, Administration, Better Business Bureau, EST, Paralysis, NPRC, Priority, Government, Organization, Foundation, Unitary state, Question and Answer, ACL, Answer, SHORT, QOL, Spinal cord, Health, Transport, HHS, Online gambling, Pharmaceutical industry, Residential care

SHORT HILLS, N.J., Aug. 31, 2022 /PRNewswire/ -- The Christopher & Dana Reeve Foundation National Paralysis Resource Center announces grant funding opportunities through its 2022 2nd Cycle Direct Effect and Priority Impact Quality of Life grants initiatives spotlighting two new grant programs, Racial Equity and Rural Unserved & Underserved Populations. Both Quality of Life grants initiatives award financial support to nonprofit organizations that mirror the Reeve Foundation's mission and are federally funded through a cooperative agreement with the United States Department of Health and Human Services, Administration for Community Living (ACL) (Cooperative Agreement Number 90PRRC0002-03-00).

Key Points: 
  • Grant Cycle Opens September 1, 2022
    SHORT HILLS, N.J., Aug. 31, 2022 /PRNewswire/ -- The Christopher & Dana Reeve Foundation National Paralysis Resource Center announces grant funding opportunities through its 2022 2nd Cycle Direct Effect and Priority Impact Quality of Life grants initiatives spotlighting two new grant programs, Racial Equity and Rural Unserved & Underserved Populations.
  • Our Racial Equity program aims to fund projects that explicitly enhances the quality of life of those individuals living at the crossroads of racial inequity and paralysis," said Mark Bogosian, Director of Quality of Life Grants Program.
  • Quality of Life grant applications are available and are to be completed online through the Reeve Foundation online grants portal .
  • The Christopher & Dana Reeve Foundation is dedicated to curing spinal cord injury by funding innovative research and improving the quality of life for individuals and families impacted by paralysis.

Castle Biosciences to Host Investor Day on Sept. 20, 2022

Retrieved on: 
Wednesday, August 24, 2022
Science, Other Science, Biotechnology, Research, Oncology, Health, Mental Health, Other Health, Patient, Research, View, Skin, DecisionDx-UM, EDT, LinkedIn, Uveal melanoma, Question and Answer, Instagram, Nasdaq, Company, Atopic dermatitis, Twitter, List of life sciences, Webcast, Health, Event, Medical device, Facebook

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.
  • Castles Investor Day event is scheduled to begin at 4:00 p.m. EDT and conclude at 6:30 p.m. EDT, followed by a Question & Answer session.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005090/en/